March 3, 2020 09:06 AM ESTUpdated 10:26 AM
R&D

Bio­gen’s ear­ly R&D chief ex­its for ARCH and Be­zos-backed an­ti-ag­ing biotech

Jason Mast

Editor

The Bio­gen mi­ni-ex­o­dus con­tin­ues, this time lead­ing to a pair of big Sil­i­con Val­ley names: Jeff Be­zos and Robert Nelsen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Fed­er­al judge throws out two drug­mak­er IRA law­suits in win for gov­ern­ment

FDA fi­nal­izes long-await­ed rule to bring lab tests un­der its purview

WuXi wants to re­gain client con­fi­dence amid claims of IP trans­fer to Chi­nese au­thor­i­ties 

Mer­ck touts up­dat­ed 21-va­lent pneu­mo­coc­cal da­ta weeks ahead of FDA de­ci­sion: Cor­rect­ed

Prime Med­i­cine re­ceives FDA clear­ance to run first prime edit­ing clin­i­cal tri­al

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times